John Stuelpnagel
Script error: No such module "Draft topics".
Script error: No such module "AfC topic".
| John Stuelpnagel | |
|---|---|
| Born | John R. Stuelpnagel |
| 🏳️ Nationality | American |
| 🎓 Alma mater | University of California, Davis (B.S) (D.V.M.) UCLA Anderson School of Management (MBA) |
| 💼 Occupation | Founder and CEO of Illumina, Inc. (1998 - 2009) Chairman and Co-founder of Fabric Genomics (2009 - Present) Chairman of 10x Genomics (2013 - Present) |
| 🌐 Website | fabricgenomics |
| Twitter= | |
John R. Stuelpnagel is an American venture capitalist, inventor, medical researcher and publicist, specializing in biotechnology.[1][2][3] He is mostly known for business and research contributions to DNA sequencing technology through co-founding Illumina, Inc.,[4] [5] a company that helped to reduce the cost of sequencing a human genome.[6][7][8] Stuelpnagel has also co-founded and ran multiple early-stage growth companies related to biotechnologies or genomics.[9][10] Stuelpnagel holds 35 issued U.S. patents.[6][11]
Background[edit]
Stuelpnagel finished his graduate studies at the University of California, Davis, where he received his B.S in biochemistry in 1979. Continuing his studies at the University of California, Davis, Stuelpnagel attained his D.V.M. within the field of Veterinary Medicine. In 1995, he entered the UCLA Anderson School of Management, where he earned a Master of Business Administration in 1997.[6]Stuelpnagel's research interests have been in the area of biotechnology and biochemistry with the main focus being on genetic sequencing and its applications in various fields of science. His work has been published in medical and biochemistry related journals. He is also co-inventor on 35 granted and 76 pending patents assigned by the United States Patent and Trademark Office (USPTO).[6][11]
Entrepreneurial activity[edit]
John Stuelpnagel co-founded and served as Chairman or CEO on a number of organization boards, including Illumina, Inc.,[12][13] 10x Genomics,[14] Fabric Genomics,[15] Element Biosciences,[16][17] Adaptive Biotechnologies Corp.[18] Inscripta, Inc.[19] and Ariosa Diagnostics, among others.[1][10] As UC Davis Veterinary Medicine notes: "The companies he established have developed and commercialized genetic products including: prenatal tests, immune sequencing for tracking the efficiency of blood cancer therapies, and a clinical informatics platform to interpret DNA sequences for diagnostic testing."[6]
Illumina, Inc.[edit]
In 1998, John Stuelpnagel, David Walt, Larry Bock, Anthony Czarnik, and Mark Chee co-founded Illumina, Inc., a biotechnology startup with the initial focus on developing DNA sequencing technology. Stuelpnagel was instrumental in building Illumina company at its early stages.[4]In particular, Stuelpnagel and Bock uncovered what would become Illumina's BeadArray technology at Tufts University and negotiated an exclusive license to that technology.[6][7] In addition, Stuelpnagel was co-inventor on numerous patents related to Illumina's development in 1998 - 2020.[11] Eventually, Illumina's technology had purportedly by 2014 reduced the cost of sequencing a human genome to US$1,000, down from a price of $1 million in 2007.[8][20][21] It is now traded on NASDAQ, NASDAQ-100 and S&P 500 under the symbols ILMN and Component.
Litigation[edit]
Stuelpnagel served as CEO of Illumina Inc. beginning in May 1998. A lawsuit brought by the Company’s then-CSO highlighted Stuelpnagel’s actions while CEO leading to claims of discrimination, retaliation, and termination against public policy (‘whistleblowing’). The jury found for the Plaintiff on all three claims and ordered an award of $7.2 million. Stuelpnagel’s actions were also included in the Czarnik v. Illumina Inc. case heard before the United States District Court for the District of Delaware.[22][23] Stuelpnagel had removed the Plaintiff’s name from lists of inventors on two patent applications, which resulted in leaving his name off the lists of Inventors on the issued patents. In its ruling for the Plaintiff, the district court was the first court to hold that reputational harm could be sufficient to establish standing in an action for correction of named inventor under 35 U.S.C. § 256.[24][25]
Notable publications[edit]
- Arnold Oliphant, David L. Barker, John R. Stuelpnagel & Mark S. Chee, "BeadArray™ Technology: Enabling an Accurate, Cost-Effective Approach to High-Throughput Genotyping" in Future Science[26]
- "Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy" in Prenatal Diagnostics[27]
- John Stuelpnagel and Bryan Roberts, "Commentary: Attacking Biology’s Complexity with New Genomics Approaches" in Fortune[28]
- John Stuelpnagel and Bryan Roberts, "An explosion of knowledge: Multiplexed interventional genomics" in Fortune[29]
Extra links[edit]
References[edit]
- ↑ 1.0 1.1 "The future of next-gen sequencing (and why an Illumina cofounder's never had his genome mapped)". MedCityNews. 13 January 2015.
- ↑ "Eight Lessons from John Stuelpnagel (Illumina)". Medium.
- ↑ "Illumina's original people are coming soon, and the mysterious Chu CHUANG, who is at the helm of the Chinese executives, has attracted $400 million in 4 years to build a cheaper DNA sequencer". MinNews.
- ↑ 4.0 4.1 "Illumina- The Origin story". www.linkedin.com.
- ↑ "Illumina: Cheap With Further Upside From Grail". Seeking Alpha.
- ↑ 6.0 6.1 6.2 6.3 6.4 6.5 "2017 Alumni Achievement Award Recipients". UC Davis Veterinary Medicine. 9 May 2017.
- ↑ 7.0 7.1 [ https://www.icmrindia.org/casestudies/catalogue/Business%20Strategy/illumina-maintaining-growth-momentum-excerpts.htm "Illumina-Maintaining Growth Momentum in a Plateauing Genome Sequencing Market"] Check
|url=value (help). IBS Center for Management Research: 18. 2017. - ↑ 8.0 8.1 "Illumina's CEO on the Promise of the $1,000 Genome -- And the Work That Remains". Recode. March 25, 2014.
- ↑ "John R. Stuelpnagel, Chairman, 10X Genomics, Inc". Wall Street Journal Markets.
- ↑ 10.0 10.1 "John Stuelpnagel". MarketScreener.
- ↑ 11.0 11.1 11.2 "Patents by Inventor John R. Stuelpnagel". Justia Patents.
- ↑ "10 Biotechnology Companies That Rule in the United States". TechFlock.
- ↑ "Illumina, Secret Giant Of DNA Sequencing, Is Bringing Its Tech To The Masses". Fast Company.
- ↑ "Stealthy 10X Genomics Raises $55.5M To Beef Up DNA Sequencing". Forbes.
- ↑ "Gene sequencing software company helps doctors personalize medicine". San Francisco Business Times.
- ↑ "Promises of a next-gen sequencing approach earn Element Biosciences a hefty Series C. Is an IPO next?". Endpoint News.
- ↑ "John R Stuelpnagel, Chairman, Element Biosciences Inc". Bloomberg.
- ↑ "Adaptive Buys Sequenta to Disrupt Cancer Diagnosis, Drug Discovery". Forbes.
- ↑ "Gene Editing Company Inscripta Acquires Solana Biosciences". GenomeWeb.
- ↑ "Illumina drops sequencing price to $4,000 - UTSanDiego.com<!— Bot generated title —>". 9 May 2011.
- ↑ Everygenome.com: Individual genome sequencing - Illumina, Inc.<!— Bot generated title —> Archived 2011-10-19 at the Wayback Machine
- ↑ "Czarnik v. Illumina, Inc., Docket No. GIC763972 (Cal. Super. Ct. 2002)". Court Records.
- ↑ "Czarnik v. Illumina, Inc., Docket No. D041034 (Cal. Dist. Ct. App. 2006)". Court Records of the Appeal.
- ↑ "Memorandum Opinion, Czarnik v. Illumina, Inc. 437 F. Supp. 2d 252 (D. Del. 2006)".
- ↑ Faryniarz v. Ramirez, No. 3:13-CV-01064 (CSH), 2015 WL 6872439 (D. Conn. Nov. 9, 2015).
- ↑ Oliphant, Arnold; Barker, David L.; Stuelpnagel, John R.; Chee, Mark S. (September 2018). "BeadArray™ Technology: Enabling an Accurate, Cost-Effective Approach to High-Throughput Genotyping". Future Science. 32 (6S): S56–S61. doi:10.2144/jun0207.
- ↑ Sparks, Andrew B.; Wang, Eric T.; Struble, Craig A.; Barrett, Wade; Stokowski, Renee; McBride, Celeste; Zahn, Jacob; Lee, Kevin; Shen, Naiping; Doshi, Jigna; Sun, Michel; Garrison, Jill; Sandler, Jay; Hollemon, Desiree; Pattee, Patrick; Tomita-Mitchell, Aoy; Mitchell, Michael; Stuelpnagel, John; Song, Ken; Oliphant, Arnold (January 2012). "Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy". Prenatal Diagnostics. 32 (1): 3–9. doi:10.1002/pd.2922. PMC 3500507. PMID 22223233.
- ↑ "Commentary: Attacking Biology's Complexity with New Genomics Approaches". Fortune. January 2019.
- ↑ "An explosion of knowledge: Multiplexed interventional genomics". Fortune.
This article "John R. Stuelpnagel" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:John R. Stuelpnagel. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
